Literature DB >> 28129544

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley Lomeli, Xiangju Kong, Mark C Kelley, Jeffrey A Sosman, Douglas B Johnson, Antoni Ribas, Roger S Lo.   

Abstract

Entities:  

Year:  2017        PMID: 28129544     DOI: 10.1016/j.cell.2017.01.010

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  117 in total

1.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

Review 2.  Emerging biomarkers for cancer immunotherapy in melanoma.

Authors:  Margaret L Axelrod; Douglas B Johnson; Justin M Balko
Journal:  Semin Cancer Biol       Date:  2017-09-14       Impact factor: 15.707

3.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Authors:  Aaron M Goodman; Shumei Kato; Lyudmila Bazhenova; Sandip P Patel; Garrett M Frampton; Vincent Miller; Philip J Stephens; Gregory A Daniels; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2017-08-23       Impact factor: 6.261

Review 4.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

5.  Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.

Authors:  Joanna Poźniak; Jérémie Nsengimana; Jonathan P Laye; Sally J O'Shea; Joey Mark S Diaz; Alastair P Droop; Anastasia Filia; Mark Harland; John R Davies; Tracey Mell; Juliette A Randerson-Moor; Sathya Muralidhar; Sabrina A Hogan; Sandra Nicole Freiberger; Mitchell P Levesque; Graham P Cook; D Timothy Bishop; Julia Newton-Bishop
Journal:  Cancer Res       Date:  2019-02-17       Impact factor: 12.701

6.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

7.  Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Authors:  Heinz Läubli; Stefan Dirnhofer; Alfred Zippelius
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064

Review 8.  Mechanisms of Resistance to PD-1 Checkpoint Blockade.

Authors:  Justin C Moser; Siwen Hu-Lieskovan
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

9.  Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.

Authors:  Yi Liao; Dingxiu He; Fuqiang Wen
Journal:  Immunogenetics       Date:  2021-07-24       Impact factor: 2.846

Review 10.  Management of V600E and V600K BRAF-Mutant Melanoma.

Authors:  Alexandra M Haugh; Douglas B Johnson
Journal:  Curr Treat Options Oncol       Date:  2019-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.